How does this study impact current management guidelines? These data highlight the importance of ecallantide administration by a health care provider knowledgeable and prepared to treat anaphylaxis.
BACKGROUND: Ecallantide is a human plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema for patients 12 years of age and older. Ecallantide is produced in Pichia pastoris yeast cells by recombinant DNA technology. Use of ecallantide has been associated with a risk of hypersensitivity reactions, including anaphylaxis. OBJECTIVE: The objective of this detailed retrospective data review was to characterize anaphylaxis cases within the ecallantide clinical trials database. METHODS: Potential cases of hypersensitivity reactions in the ecallantide clinical development program were identified by examining reported adverse events. The National Institute of Allergy and Infectious Disease criteria were used to identify those events that were consistent with anaphylaxis; these cases were then reviewed in detail. Results from investigational antibody testing also were examined. RESULTS: Among patients who received subcutaneous ecallantide (n [ 230 patients; 1045 doses of 30 mg ecallantide), 8 patients (3.5%) had reactions that met the National Institute of Allergy and Infectious Disease criteria for anaphylaxis; none occurred on first exposure to the drug. All 8 reactions had symptom onset within 1 hour of exposure and cutaneous manifestations commonly observed in type I hypersensitivity reactions. All the reactions responded to standard management of type I hypersensitivity reactions and resolved without fatal outcomes. IgE antibody testing to ecallantide or P pastoris was Hereditary angioedema (HAE) is a rare disease characterized by prolonged, unpredictable attacks of nonpitting, nonpruritic edema of the subcutaneous (SC) tissue and mucosa. It is caused by a deficiency in functional C1-inhibitor, a serine-protease inhibitor of the plasma kallikrein-kinin, coagulation and complement systems. Swelling occurs most commonly in the face, extremities, gastrointestinal tract, and genitalia. 1 Swelling of the laryngeal area is of serious medical concern because it can result in airway compromise and asphyxiation. 2, 3 During an HAE attack, unregulated plasma kallikrein activity results in excessive production of bradykinin, a potent vasodilator that causes the symptoms of swelling and pain characteristic of an HAE attack. [4] [5] [6] Ecallantide (KALBITOR; Dyax Corp, Burlington, Mass) is a recombinant protein inhibitor of human plasma kallikrein produced in the yeast Pichia pastoris. 7, 8 It is indicated for the treatment of acute attacks of HAE of patients 12 years of age and older. 9 The safety and efficacy of ecallantide were demonstrated in 2 randomized, double-blinded, placebo-controlled phase 3 studies, Evaluation of DX-88s Effects in Mitigating Angioedema (EDEMA) 3 Double Blind (EDEMA3 Ò -Double Blind) and EDEMA4 Ò (Dyax Corp, Burlington, Mass). [10] [11] [12] In both studies, clinical efficacy was evaluated by using 2 validated, HAEspecific, patient-reported outcomes: the Treatment Outcome Score and the Mean Symptom Complex Severity score. 13 The Treatment Outcome Score is a measurement of symptom response to treatment, and the Mean Symptom Complex Severity score is a point-in-time measurement of symptom severity. When using both measurements, 30 mg of SC ecallantide was superior to placebo in relieving symptoms and in decreasing the severity of attacks. 10, 11 Symptom relief was durable, with sustained symptom relief observed up to 24 hours after ecallantide treatment. 10, 11 The use of ecallantide is associated with anaphylaxis in 3% to 4% of treated patients. 9 The drug, therefore, should only be administered by a health care professional with appropriate medical support to manage anaphylaxis and HAE. 9 In this analysis, we conducted a retrospective review of cases of anaphylaxis reported during the clinical development program for ecallantide to ascertain if these cases represent type I hypersensitivity reactions. The analysis included all the patients treated with either SC or intravenous (IV) ecallantide during clinical trials: EDEMA0, EDEMA1, EDEMA2, EDEMA3 (DoubleBlind and Repeat-Dosing arms), EDEMA4, and DX-88/19. Only the SC formulation of ecallantide is currently approved and available for clinical use in the United States.
METHODS
This analysis included all cases of potential hypersensitivity reactions identified in the ecallantide HAE clinical development program (EDEMA0, EDEMA1, EDEMA2, EDEMA3 [DoubleBlind and Repeat-Dosing], EDEMA4, and DX-88/19). Ecallantide was administered by IV in EDEMA0 and EDEMA1; either IV or SC in EDEMA2; and only SC in EDEMA3 (Double Blind and Repeat-Dosing arms), EDEMA4, and DX-88/19. A change in the ecallantide manufacturing process occurred during EDEMA2 in which an additional purification step was added. This step decreased the amount of residual P pastoris host cell protein in the drug product. All SC doses of the drug were produced with this additional purification step. IV doses of ecallantide administered in EDEMA0, EDEMA1, and portions of EDEMA2 did not include the additional purification step, and, therefore, the residual amounts of P pastoris differed between the SC and IV doses. All the studies were institutional review board-approved, and all the patients provided written informed consent. For inclusion in the clinical studies, patients had to be !10 years old, except in EDEMA0, in which the subjects were !18 years of age, with moderate-to-severe acute HAE attacks (DX-88/19 also included mild attacks).
Identification and adjudication of hypersensitivity reactions
The database listing of treatment emergent adverse events, defined as those events with onset during or after ecallantide dosing, was searched for cases that had adverse event terms that may be associated with type I hypersensitivity reactions. These terms included "adverse drug reaction," "anaphylaxis," "anaphylactic reaction," "anaphylactoid reaction," "hypersensitivity," "erythema," "flushing," "hot flush," "pharyngeal edema," "laryngeal edema," "pruritus," "pruritus generalized," "rash," "rash erythematous," "rhinitis allergic," "rhinorrhea," "throat irritation," "urticaria," "urticaria localized," "dyspnea," and "wheezing." "Angioedema" was not included in the list of terms. The National Institute of Allergy and Infectious Disease (NIAID) clinical criteria for diagnosing anaphylaxis, which was used to determine anaphylaxis in this study, are shown in Table I. 14 Records of cases for any treatment emergent adverse events with these terms then underwent a manual medical review to identify potential hypersensitivity reactions, with considering factors such as timing of treatment emergent adverse events in relationship to dose (ie, occurred within 24 hours of study drug administration), accompanying symptoms, causality assessment of the investigator (typically reported as possibly, probably, or definitely related to study drug), and any other available clinical information.
Rechallenge: skin test and test dose procedures
Patients who experienced a hypersensitivity reaction in EDEMA1, EDEMA2, or EDEMA3 were eligible to undergo rechallenge procedures to further define their sensitivity to ecallantide. The rechallenge testing procedure was separated into 2 phases: a skin-testing phase and a test-dosing phase. The patients proceeded through each phase, depending on their reaction to ecallantide after each dose and the investigator's discretion. After signing the separate informed consent, the patients entered the skin-testing phase of the rechallenge. Escalating amounts of ecallantide, along with positive and negative controls (histamine and saline solution, respectively), were administered by a series of skin pricks and intradermal injections. If skin testing was negative, then the patients could enter the test-dosing phase. The patients in the test-dosing phase received escalating doses of ecallantide through a series of 4 distinct IV infusions, of 3, 4.5, 7.5, and 15 mg of ecallantide, each separated by 30 minutes. The patients did not undergo any desensitization before rechallenge testing. If a patient experienced a positive reaction to ecallantide at any time during the rechallenge, and the investigator assessed the symptoms as indicative of a hypersensitivity reaction, then the rechallenge procedure was stopped.
Antibody testing
The assays used to measure antibody responses to ecallantide evolved during clinical development. Immunogenicity of ecallantide was initially measured by using an indirect ELISA for detection of non-IgE (IgM, IgG, or IgA) to ecallantide and IgE to ecallantide or P pastoris. These assays were used in the EDEMA0, EDEMA1, and EDEMA2 studies. During the clinical development of ecallantide, Dyax developed and validated new antibody assays in line with industry consensus recommendations and International Conference on Harmonisation guidelines(http://www.ich.org/products/guidelines.html). The new assays consisted of an electrochemiluminescent (ECL) ligand-binding assay designed to detect all classes of antibodies (IgM, IgG, IgA, and IgE) to ecallantide in human serum by using the Meso Scale Discovery detection system (Meso Scale Discovery, Rockville, Md) and direct ELISAs for detection of IgE to ecallantide or P pastoris proteins.
These new assays were used in the EDEMA3, EDEMA4, and DX-88/19 studies to screen, confirm, and titer all classes of antiecallantide antibodies (IgM, IgG, IgA, and IgE). The new assays represented significant improvements in assay format. The ECL assay in particular has a greater dynamic range and less potential for drug interference. Detailed methodology of these assays is provided in the Supplementary Methods (in this article's Online Repository at www.jaci-inpractice.org). The performance characteristics of each of the assays used in the clinical development program for ecallantide are provided in Table E1 (in this article's Online Repository at www.jaci-inpractice.org). To be conservative, patients were considered positive if they had a positive result in the initial screening but the titer and/or confirmatory result were missing. Patients who had 1 positive serum sample test were considered to be positive for the rest of the clinical development program, regardless of the presence of any subsequent negative test results.
RESULTS

Hypersensitivity
reactions after ecallantide administration that met the definition of anaphylaxis based on NIAID criteria During the ecallantide clinical development program, 297 unique patients with HAE were treated with 1302 doses of ecallantide (including IV and SC doses). Of the 297 unique patients, 230 patients received 1045 doses of SC ecallantide. The mean patient age was 34.6 years (range, 10-78 years); 65.7% of patients were female patients, and 85.4% were white. Potential hypersensitivity reaction cases from 32 patients (20 SC, 12 IV) were identified for further analysis. Among these patients, 13 (8 SC, 5 IV) had reactions that met the NIAID criteria for anaphylaxis, and 19 (10 SC, 7 IV, 2 SC and IV) had reactions that did not meet the NIAID criteria for anaphylaxis ( Figure 1 ; see Table E2 in this article's Online Repository at www.jaci-inpractice.org for details of reactions that did not meet NIAID criteria). To better understand the cases of anaphylaxis, these NIAID-positive cases were characterized in further detail (Table II) . After SC administration, there were no cases of anaphylaxis that occurred on the first exposure to the drug. All 8 NIAIDpositive reactions after SC administration had an onset of symptoms within 1 hour of drug exposure, and all were associated with cutaneous symptoms, such as urticaria, pruritus, erythema, or flushing. None of the reactions required measures beyond standard management of type I hypersensitivity (eg, epinephrine, antihistamines, corticosteroids, IV fluids, supplemental oxygen), and all resolved without fatal outcomes. One patient (Table II , patient no. 3) was transported to the emergency department and held for overnight observation after SC ecallantide administration in episode 5. This patient was discharged the following morning, and all symptoms resolved without further sequelae.
After IV dosing of ecallantide, 5 reactions met the NIAID criteria for anaphylaxis (Table II) . In contrast to cases of anaphylaxis after SC dosing, all of these reactions occurred on the first exposure. Three of the IV reactions had a symptom onset within 60 minutes of exposure, and 2 reactions had an unknown time of onset. Two of the 5 patients with IV reactions presented with cutaneous manifestations suggestive of type I hypersensitivity, including urticaria and/or pruritus. Four of the IV reactions were associated with nasal symptoms suggestive of histamine release, such as sneezing, rhinorrhea, and throat itching; urticaria; or other systemic symptoms. All of these reactions resolved with epinephrine, corticosteroids, antihistamines and/or bronchodilators, or without specific therapy for the reaction. There were no fatal outcomes, and no reactions after IV administration required hospitalization. A summary of the clinical characteristics of the hypersensitivity reactions that met the NIAID criteria for anaphylaxis after both SC and IV dosing is provided in Table III .
Rechallenge outcomes
Of the 8 patients with reactions that met the NIAID criteria for anaphylaxis after SC ecallantide, 5 patients had additional exposure to ecallantide (Table II; patient nos. 1, 5, 6, 7, and 8). This re-exposure occurred either as part of the rechallenge procedure or during additional treatment episodes. The outcomes of these reexposures were as follows: patient no. 1 had a hypersensitivity reaction on rechallenge. The reaction included a positive skin test and anaphylactic reaction to an IV partial dose of ecallantide after pretreatment with hydroxyzine and prednisone. This patient did not receive any additional doses of ecallantide. Patient no. 5 developed a 4-mm wheal after an undiluted dose of ecallantide (0.2 mg) during a skin prickepuncture test and did not receive any additional doses of ecallantide after this reaction. With the remaining 3 cases (Table II; 
Three of the 5 patients (Table II ; patient nos. 10, 11, and 13) with hypersensitivity reactions that met the NIAID criteria for anaphylaxis after IV ecallantide underwent the skin-testing and test-dose procedure. Two of these patients had a negative skin test but displayed symptoms of hypersensitivity during the testdose procedure. The third patient had a negative skin test and test dose but did not receive any additional doses of ecallantide.
Antibody status
As a general screen to detect the presence of antidrug antibodies (any class), antibody testing to ecallantide was conducted with all the patients in the clinical development program for ecallantide. In the overall population (both IV and SC), a total of 60 of 297 patients (20.2%) were positive for anti-ecallantide antibodies (IgG, IgA, IgM, or IgE), but the clear majority of these patients did not have hypersensitivity reactions. All 8 patients with anaphylaxis after SC administration tested positive for anti-ecallantide antibodies (any class). There was a lack of consistent positivity for IgE antibodies to ecallantide or P pastoris among these 8 patients with anaphylaxis. (Table II) . Furthermore, antibody status was not reliably predictive of future hypersensitivity reactions with these patients. Patient nos. 6 and 7 tested positive for anti-ecallantide IgE but displayed no symptoms of hypersensitivity after subsequent doses of ecallantide. Patient no. 8 tested positive for both anti-ecallantide IgE and antieP pastoris IgE before treatment in episode 13 but did not have a hypersensitivity reaction after a subsequent dose in episode 14. In addition, none of the patients with reactions that met the NIAID criteria for anaphylaxis after IV administration tested positive for IgE antibodies to ecallantide or P pastoris (Table II) . Unrelated to hypersensitivity, but important to the discussion of antibody testing, is the observation that anti-ecallantide antibody 
DISCUSSION
The clinical development program of ecallantide included studies in which ecallantide was administered IV (EDEMA0, EDEMA1, and EDEMA2) and SC (EDEMA2, EDEMA3-Double-Blind, EDEMA3eRepeat-Dosing, EDEMA4, and DX88/19), and hypersensitivity reactions occurred after either route of administration. Symptoms included pruritus, urticaria, erythema, flushing, dyspnea, chest discomfort, dizziness, nausea, hypotension, and laryngeal edema. In total, there were 13 of 297 patients (4.4%) treated either with IV or SC ecallantide, who had potential hypersensitivity reactions that met the NIAID criteria for anaphylaxis; 8 of 230 patients (3.5%) treated with the approved SC formulation had potential hypersensitivity reactions that met the NIAID criteria. The rates reported here are consistent with what is included in the current product labeling for ecallantide (3% to 4%). 9 After SC administration, no cases of anaphylaxis occurred on first exposure to the drug. The timing of symptom onset was suggestive of a type I hypersensitivity reaction because symptoms in all cases after SC administration began within 1 hour of drug exposure. In addition, all of the cases were associated with cutaneous manifestations also suggestive of an IgE-mediated hypersensitivity reaction, such as urticaria, pruritus, erythema, or flushing. However, a small subset of these patients did not have recurrence of their reaction upon subsequent reexposure, which argues against a type I hypersensitivity etiology in those cases. The reactions, except one, did not require any treatments beyond those typically used in managing type I hypersensitivity reactions, and, although there was 1 hospitalization, there were no fatal outcomes.
The pattern of hypersensitivity reactions after IV administration was different from that after SC administration, which suggests that IV reactions may be mediated by a different mechanism, such as non-IgEemediated mast cell activation. Notably, all reactions that met the NIAID criteria for anaphylaxis after IV administration occurred on first exposure to the drug, which suggests that patients may already have been presensitized to the drug product, such as a component related to P pastoris, the cells used to manufacture ecallantide. However, none of the patients with anaphylaxis after IV infusion tested positive for antieP pastoris IgE. The change in the purification process of ecallantide that occurred during EDEMA2 also may be part of the explanation. All SC doses of ecallantide included an additional purification step, which reduced residual P pastoris, and this could potentially explain the difference in the observed pattern of hypersensitivity reactions after SC and IV ecallantide. However, there are not sufficient data to support any particular mechanism to explain the pattern of reactions.
As summarized in Table II , not all cases of hypersensitivity (6 of 13) that met the NIAID criteria for anaphylaxis were treated with epinephrine, the treatment of choice for anaphylaxis. A possible explanation for this finding is that, early in clinical development, a causal link between ecallantide administration and hypersensitivity was not clear and the extent of anaphylaxis risk was not understood. At the time of some of the events, investigators may not have necessarily viewed the constellation of symptoms as representing anaphylaxis. Only as the clinical development program progressed did the extent of anaphylaxis risk become apparent, which led to the boxed warning for *Rows with data in bold represent reactions that met NIAID criteria for anaphylaxis. †Total treatment episodes across all ecallantide clinical studies of HAE; the administration of second doses of ecallantide as either dose B or for severe upper airway compromise is not counted as a separate treatment episode.
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anaphylaxis and the requirement that ecallantide is administered by a health care professional with appropriate medical support to manage anaphylaxis and HAE.
Results from antidrug IgE antibody testing did not confirm the mechanism of the hypersensitivity reactions. There was a lack of consistent positivity to IgE antibodies to ecallantide or P pastoris, and none of the IV anaphylaxis cases had a positive antidrug IgE result. In addition, some patients tested positive for antidrug IgE but did not develop symptoms of hypersensitivity after subsequent drug exposure. It should be noted that detection of circulating antidrug IgE antibodies can be challenging due to the association of IgE on the surface of mast cells and resulting low concentration of IgE in the circulation. Skin testing is a common diagnostic procedure for evaluating potential drug hypersensitivity. 15, 16 In the cases reviewed here, many patients with reported hypersensitivity reactions did not undergo skin testing. Due to this major limitation in the data, the predictive value of skin testing remains unknown.
Due to the lack of skin testing data and the insufficient predictive value of in vitro antidrug IgE antibody testing, a reliable diagnostic test for assessing hypersensitivity remains unavailable, and the possible mechanism of the reactions remains unknown. Nonetheless, a review of the clinical presentations in these anaphylaxis episodes provided meaningful information. Due to the overlap of symptoms in anaphylaxis and HAE attacks, distinguishing between the 2 events after ecallantide administration is an important consideration for health care professionals. As observed in these cases, rapid onset of symptoms after dosing, the presence of cutaneous manifestations commonly associated with mast cell degranulation (eg, urticaria), and response to standard type I hypersensitivity reaction treatment were consistently observed in anaphylaxis episodes after SC ecallantide administration. It should be noted that the same clinical presentation may be observed after complement-mediated mast cell activation but the data available from the clinical development program for ecallantide do not allow definitive mechanistic conclusions to be made.
CONCLUSION
Ecallantide use is associated with a low but important risk of anaphylaxis. The underlying mechanism for these anaphylaxis episodes is unclear, and no predictive risk factor could be identified. The clinical features described herein may serve as helpful indicators to guide clinicians in evaluating cases of potential hypersensitivity reactions after ecallantide administration. 
SUPPLEMENTARY METHODS Antibody Assays
The assays used to measure antibody responses to ecallantide evolved during clinical development. Immunogenicity (non-IgE) of ecallantide was initially measured by using an ELISA format. This method was replaced with a bridging ECL format that had increased sensitivity and dynamic range, and less potential for drug interference. Assays to detect antibodies to P pastoris host cell proteins were initially developed with surrogate controls that required multiple assay formats on the same plate. These methods were refined with the introduction of a unique bifunctional control that allowed for a single direct binding format. The ECL anti-ecallantide antibody assay and ELISA for ecallantide IgE and P pastoris IgE were used in both pivotal phase 3 clinical studies EDEMA3 and EDEMA4. Details of the assay methods are provided in Supplementary Methods sections Assay 1 and Assay 2.
Non-IgE anti-ecallantide antibodies ELISA assays ELISA methods were developed for the detection of antiecallantide antibodies. These assays were termed non-IgE antiecallantide responses because the secondary or detection antibody could possibly detect IgA and IgM antibodies in addition to IgG antibodies. Assay 1. Plates were coated with ecallantide standard, and assay reference standards, controls, and human serum were added and incubated. After incubation, anti-ecallantide antibodies bound to the plate were detected by using a secondary donkey antihuman IgG-heavy and light chain antibody conjugated to horseradish peroxidase (HRP). Because no human anti-ecallantide antibodies were available, a purified rabbit polyclonal antiecallantide antibody was used as the positive control that was detected by secondary goat-antirabbit IgG Fc conjugated to HRP. Also, 3,3',5,5'-tetramethylbenzidine (TMB) was the colorimetric substrate used for reading at an optical density (OD) of 450 to 650 nm. Samples were considered positive for antiecallantide antibodies when OD readings were higher than the assay cut point, which was set at 2 times the mean OD values for the human serum negative controls. Data were reported as OD values.
Assay 2. Plates were coated with ecallantide standard, and assay reference standards, controls, and human serum were added and incubated. After incubation, anti-ecallantide antibodies bound to the plate were detected by using a secondary goat-antihuman IgG, IgA, IgM, heavy and light chain antibody conjugated to HRP. Because no human anti-ecallantide antibodies were available, a purified rabbit polyclonal anti-ecallantide antibody was used as the positive control, which was detected by secondary goateantirabbit IgG conjugated to HRP. TMB was the colorimetric substrate used for reading at an OD of 450 nm. Samples were considered positive for anti-ecallantide antibodies when OD readings were higher than the prespecified assay cut point of 0.392 OD (20.53 U/mL). This cut point was derived from the means AE 2 SDs of OD values from 60 human serum negative controls. Data were reported as OD U/mL. A competitive ELISA-immunodepletion assay also was developed by using the same reagents to determine the specificity of samples that were positive in the screening assay. In this assay, antibody-positive serum samples spiked with ecallantide (100 ng/mL) compete for solid phase ecallantide bound to the plate. A reduction in signal of 50% or greater indicated specificity to ecallantide.
Non-IgE anti-ecallantide antibodies ECL assay
A Meso Scale Discovery bridging assay with ECL detection to screen, confirm, and titer all classes of anti-ecallantide antibodies was developed. In this assay, ecallantide was conjugated with either biotin or ruthenium, and these reagents were used for both capture and detection. Assay reference standards, controls, and serum samples were incubated with a mixture of both biotinylated and ruthenylated ecallantide, which allowed polyclonal anti-ecallantide antibodies to form a bridge. The mixture was added to streptavidin-coated plates to bind the anti-ecallantide antibody complexes. A read buffer that contained tripropylamine was added, and an electric potential was applied to the plates. The resulting ECL signal was proportional to the concentration of the anti-ecallantide antibody present in the plasma sample. Because human anti-ecallantide positive control antibodies were not available, a purified rabbit anti-ecallantide antibody spiked into human serum was used as the positive control.
Samples were considered positive in the screening assay when the ECL counts were higher than the assay cut point. Plate lotespecific cut points were established based on ECL counts from 30 patients who were ecallantide treatment naive. To confirm the detection of anti-ecallantide-specific antibodies, the assay was repeated in the presence and absence of 12.5 mg/mL ecallantide. If the presence of ecallantide decreased the signal by at least 33% or to the cut point or below, then the sample was confirmed as true positive; otherwise, the sample was considered negative for anti-ecallantide antibodies. A third assay then was run to establish the anti-ecallantide antibody titer. Confirmed positive samples were serially diluted, and the titer was reported as the reciprocal of the dilution that resulted in the last positive (above cut point) ECL response.
IgE anti-ecallantide antibody ELISA
The assay used a bifunctional reagent, which consisted of a covalently linked purified human IgE with an affinity purified rabbiteanti-ecallantide antibody. This allowed for specific recognition of the coated ecallantide via the rabbit antibody, while acting as a control for the antihuman conjugate through the IgE moiety. Plates were coated with ecallantide standard, and assay reference standards, controls, and serum were added and incubated. After incubation, anti-ecallantide antibodies bound to the plate were detected by using a secondary mouse anti-human IgE antibody conjugated to HRP. TMB was the colorimetric substrate used for reading at an OD of 450 nm. Samples were considered positive for anti-ecallantide antibodies when OD readings were higher than the prespecified assay cut point. A fixed cut point was established for the assay with a value of 0.1 OD units. By using this cut point, the estimated sensitivity for the assay would be 0.36 ng/mL.
IgE antieP pastoris antibody ELISA
This assay used a bifunctional reagent that consisted of a covalently linked purified human IgE with an affinity purified rabbit antieP pastoris antibody, which allowed for specific recognition of the coated P pastoris protein via the rabbit antibody while acting as a control for the antihuman conjugate through the IgE moiety. Plates were coated with P pastoris fraction A standard, and assay reference standards, controls, and serum were added and incubated. After incubation, antieP pastoris antibodies bound to the plate were detected by using a secondary mouseeantihuman IgE antibody conjugated to HRP. TMB was the colorimetric substrate used for reading at an OD of 450 nm. Samples were considered positive for antieP pastoris antibodies when OD readings were higher than the prespecified assay cut point. A fixed cut point was established for the assay with a value of 0.08 OD units. By using this cut point, the estimated sensitivity for the assay would be 0.52 ng/mL. 
